Savient Pharmaceuticals Completes Puricase Phase 3 Studies For Treatment-Failure Gout

Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced the completion of the in-life portion of its two pivotal Phase 3 clinical trials for Puricase® (pegloticase) in patients with treatment-failure gout, an orphan indication. Puricase is a pegylated recombinant mammalian urate oxidase that is being developed to control hyperuricemia and its clinical consequences in patients for whom conventional therapy is contraindicated or has been ineffective. [click link for full article]

More: continued here

Filed under: Clinical Trials on October 20th, 2007